Research Of Iressa For Patients With Advanced NSCLC

Objective: To observe the effects and side effects of iressa, gemcitabin/cisplatin, taxotere/cisplatin in the treatment of patients with advanced non small cell lung cancer. To evaluate the value of iressa in the treatment of NSCLC.Patients and methods:(1) General condition of the patients: 43 patients with definite diagnosed of developed non-small cell lung cancer admitted into Shandong Provincial Hospital from November 2003 to November 2006 were enrolled into our study, including 12 males and 31 females, median age 52.4 years (ranged 38-75 years). Some patients in early state of lung cancer,small cell lung cancer , accepted operations or radioactive therapy were excluded. They were grouped into 3 groups,group I was experiment group,group II and group III were the controlled groups. There were no sex ,age differences of the three groups.(2) Clinical treatment: The patients in group I were given oral iressa at a dose of 250 mg per day for 30 days .This was repeated at least 4 cycles. The patients in group II were treated with taxol +cisplatin per three weeks and repeated at least 4 cycles. The patients in group III were treated with gemcitabin +cisplatin per three weeks and repeated at least 4 cycles.All the patients can received symptomatic treatment such as thoracentesis, paracentesis pericardii and drug which can enhance their immunity.Result:(1) Short-term effects: group I 41.2%, group II 40.0%, group III 33.3%.Mediea survival time: group I 11.5. 9.5 months, group II 8.7 months, group III 8.3 months. (2) the clinical effects of the patients(3)side effects: 1 patients in group I had to stop the treatment because of severe empsyxis ,severe diarrhea and raise of aminopherase. There was no other side effect which could not be treated.Conclusion:1. Iressa is more effective than taxol and gemcitabin for advanced NSCLC.2. It can be considered as a second-line drug for developed non-small cell lung cancer patients, especially for patients who have no effect with other chemical drugs.3. For female patients with advanced adenous lung cancer, Iressa has noticeable effect.